NEW DELHI: Jubilant Life Sciences on Tuesday reported a 65.41% rise in consolidated net profit to Rs 70.68 crore during JanuaryMarch against a year ago. “We have delivered strong and consistent performance through the year thereby achieving our highest-ever EBITDA of Rs 1,291 crore in 2015-16,” said Shyam S Bhartia, chairman, and Hari S Bhartia, co-chairman and MD, Jubilant Life Sciences. The growth has been led by the company’s pharmaceuticals segment, specifically its speciality pharmaceuticals (sterile products) business.
May 20, 2018 14:14 IST
May 20, 2018 11:33 IST